Objectives: Fluoroquinolones are widely used in geriatric patients, but elderly patients are known to be at increased risk of decline in renal function. As fluoroquinolones usually exhibit a dominant renal elimination pathway, reduced dosage regimens are often used in geriatric patients. Our objective was to assess the capability to reach a pharmacokinetic -pharmacodynamic target of efficacy with such reduced dosage regimens of ofloxacin, levofloxacin and ciprofloxacin in elderly patients.
Introduction
Fluoroquinolones are widely used in geriatric patients, both in community and healthcare facilities. Whereas norfloxacin, ofloxacin and ciprofloxacin are mainly used for their predominant Gram-negative activity, the latest agents, such as levofloxacin and moxifloxacin, have good Gram-negative activity and, in addition, further improved activity against Gram-positive and atypical and anaerobic bacteria. 1, 2 Fluoroquinolones can also be used to treat infections such as urinary tract infections, community-acquired pneumonia, acute exacerbation of chronic bronchitis and sinusitis. 3 The emergence of resistant strains is a growing problem worldwide, 4 -6 especially with multidrug-resistant Pseudomonas aeruginosa as a cause of nosocomial infections. 7 A careful use of currently available agents and the choice of an optimal dosage regimen are critical to maximize microbiological and clinical outcomes, and avoid further development of resistance. 8 Elderly patients are known to be at increased risk of drug adverse events, and drug interactions, mainly because of polymedication and age-associated physiological changes. Between age 30 years and age 80 years, a decline in the water:lipid ratio, cardiac output, renal function and hepatic function are observed. Drug absorption can also be impacted by a decline in acidity and alterations in intestinal motility and transit time that occur progressively with age. 9 As fluoroquinolones can exhibit both renal excretion and hepatic metabolism, with usually a renal-dominant elimination pathway, elderly patients were shown to have changes in fluoroquinolone pharmacokinetic parameters, with a reduced rate of renal elimination, partially explained by the common decline in creatinine clearance. Therefore, reduced dosage regimens are often used to account for the decline in renal elimination.
Our objective was to assess the capability to reach a pharmacokinetic -pharmacodynamic target of efficacy with reduced dosage regimens of ofloxacin, levofloxacin and ciprofloxacin in elderly patients, using Monte Carlo simulations.
Methods
Pharmacokinetic parameters reported in the literature for levofloxacin, ciprofloxacin and ofloxacin were collected. A selection of studies undertaken in humans, reporting mean (or median) and standard deviation (or coefficient of variation) for each parameter, was done.
Because of the methodology used, compartmental pharmacokinetic studies were favoured. When such information was available, the parameters obtained specifically in elderly patients were selected. Finally, the statistical relationships between the pharmacokinetic parameters and physiological variables (such as age, weight and creatinine clearance) identified in these studies were also incorporated in our models.
The pharmacokinetic parameters and statistical relationships finally retained are presented in Table 1 . From this information, three compartmental pharmacokinetic models were built, including an absorption compartment and a central compartment for ofloxacin, with a supplemental peripheral compartment for levofloxacin and ciprofloxacin. The systems of ordinary differential equations for the three models were determined.
Anthropometric data were collected from a cohort of 300 elderly patients of a geriatric university hospital (S. Goutelle and R. Faure, University Hospitals of Lyon, France, personal communication). A mean age of 85.4+6 years, a mean weight of 63.5+10.6 kg and a mean creatinine clearance of 47.6+23.3 mL/min (estimated with the CockcroftGault formula) were recorded and used in the simulation step of the study.
From the mean values and standard deviations of pharmacokinetic parameters and anthropometric variables, 1000 simulated patients were created by Monte Carlo simulations with an assumption of a normal distribution. The range of possible values was restricted to the 95% CI to discard marginal variable values in the random process. Except when statistical relationships between parameters and/or variables were identified in the literature, independence between parameters was assumed. The simulations were performed using the normrnd instruction of MATLAB software (MathWorks, Natick, MA, USA). We assumed no intra-individual variability of pharmacokinetic parameters and variables during the time of the simulation.
As a dosage regimen reduction is recommended in patients with altered renal function, a situation that is common in elderly patients, three different regimens were included in the simulation of 10 day therapies (Table 2) , based on actual recommendations. 15 -19 Among different recommendations available in Europe, EUCAST guidelines were used to set the standard dosage regimens. Since no specific regimen is proposed for patients with renal impairment in these guidelines, the French Summaries of Product Characteristics were used to set the reduced dosage regimens.
The time course of fluoroquinolone serum concentrations was described using the corresponding system of differential equations.
For ofloxacin, Creatinine clearance estimated with the Cockcroft-Gault formula. Leroy et al.
where X(1) is the amount of ofloxacin in the absorption compartment (mg), X(2) is the amount of ofloxacin in the central compartment (mg), F is the bioavailability, Ka is the absorption rate constant (per hour) and Kel is the elimination rate constant (per hour). For ciprofloxacin and levofloxacin,
where X(1), X(2) and X(3) are the amount of ciprofloxacin or levofloxacin in the absorption, central and peripheral compartment (mg), respectively, F is the bioavailability, Ka is the absorption rate constant (per hour), Kel is the elimination rate constant (per hour) and Kcp and Kpc are intercompartmental transfer rate constants (per hour). The serum concentration was calculated using the following formula:
where C is the serum concentration, X(2) is the amount of fluoroquinolone in the central compartment and V is the volume of distribution of the central compartment for ciprofloxacin and levofloxacin and the apparent volume of distribution for ofloxacin. We used MATLAB software to solve the system of ordinary differential equations with the function ode45.
The pharmacokinetics-pharmacodynamics of fluoroquinolone have been well defined and several parameters have been proposed to predict clinical efficacy (C max /MIC, AUC/MIC, AUC/MPC and t.MIC; where MPC stands for mutant prevention concentration). 20 -24 Because the AUC/MIC ratio has been reported to have the strongest correlation with clinical outcomes and development of resistance to fluoroquinolones in a non-clinical model of infection, 25 -28 it was chosen as a substitution criterion to evaluate treatment efficacy in our model. The attainment of a total fAUC/MIC ratio .100, which is the higher target recognized by EUCAST, 16 -18 was set as the pharmacodynamic target. The unbound fraction (f) was set to 0.7 for ciprofloxacin and levofloxacin and to 0.75 for ofloxacin. Typical MICs 29 were considered during the simulations, ranging from 0.5 to 4 mg/L.
A breakpoint concentration 90 (BC 90 ), defined as the MIC value above which ,90% of patients reach the efficacy target, was calculated. Whatever the antimicrobial agent was, there were significant differences in the mean AUC according to the regimen considered (t-test, P, 0.001).
Results

Mean
The percentage of patients reaching the efficacy target as a function of MIC is reported in Table 3 and the evolution of this percentage is represented in Figure 1 . When considering an MIC of 2 mg/L only 3.4% and 30.2% of patients with moderate renal impairment reached the efficacy target for ciprofloxacin and ofloxacin, respectively. This figure dropped to 0% and 0.8% in cases of severe renal impairment for ciprofloxacin and ofloxacin, respectively. The BC 90 s of each regimen and each antimicrobial agent are reported in Table 4 . It should be noted that for ciprofloxacin, .80% of patients with severe renal impairment were unable to reach the target fAUC/MIC with an MIC as low as 1 mg/L, whereas for levofloxacin, all simulated patients reached the efficacy target until an MIC of 4 mg/L.
Discussion
Fluoroquinolones represent an important class of antibiotics, but the emergence of bacterial resistance requires optimizing fluoroquinolone use. The pharmacokinetics of these drugs show a significant renal elimination, which can be reduced in the case of renal impairment, frequently encountered in the geriatric population. Therefore, dosage reduction is recommended in patients with renal failure, whether with a reduction in dose unit or an increase in the dosing interval. It seems necessary to verify if such reduced doses were suitable for clinical practice.
From published pharmacokinetic data, and anthropometric data measured in a cohort of hospitalized elderly patients, a simulation study was conducted to test the usefulness of dose reductions based on renal function in elderly patients. Three fluoroquinolones were modelled, and the dosages commonly used have been tested. Efficacy was evaluated by observing the value of the index fAUC/MIC, considering MICs ranging from 0.5 to 4 mg/L.
Our study showed that dose reductions according to renal function are generally well adapted to geriatric patients when considering bacteria with low MICs. Indeed, for MICs ,1 mg/L, Efficacy of fluoroquinolone reduced dosage regimens in the elderly 2209 JAC all simulated patients reach the efficacy target (fAUC/MIC .100) for all fluoroquinolones tested. However, with higher values of MIC, the proposed regimens were inefficient for patients with moderate or severe renal impairment, mainly to ciprofloxacin and ofloxacin (0% and 0.8% in cases of severe renal impairment when considering an MIC of 2 mg/L).
More generally, the AUC values observed in patients with renal impairment after administration of a reduced regimen are significantly lower than those observed in patients without renal Leroy et al.
impairment. This suggests that the proposed dose reduction does not allow the same exposure to be achieved in these patients as in patients without renal impairment. This relative under-exposure could be responsible for treatment failure or facilitate the development of resistant strains. 30 The methodology used here, although it has already been applied on several occasions to evaluate the usefulness of therapeutic strategies, 7,31 -34 has some limitations that should be discussed. First, the blood concentrations of fluoroquinolones were estimated using pharmacokinetic mono-compartmental (ofloxacin) or bi-compartmental models (levofloxacin and ciprofloxacin). More complex and perhaps more efficient models could have been used. However, the structural models used in this study were reported to present satisfactory predictive capabilities for the blood levels of these drugs in their original publications. On the other hand, it was not possible to find publications specifically mentioning pharmacokinetic parameters obtained in elderly patients for all drugs studied. A slight difference in predictions could be considered for this reason, but taking into account the weight and renal function of elderly patients in these models should have reduced this potential source of bias. Moreover, in the absence of a single source for all relevant parameter values required for modelling (mean and standard deviation), it was sometimes necessary to extract information from several different publications. Finally, some assumptions were necessary to perform simulations: Gaussian distribution of pharmacokinetic parameters and physiological variables, assumption of independence of parameters and assumption of absence of intra-individual variability during the 10 days of simulated therapy.
This study brings up the possibility that dose adjustments based on renal function are not always suitable for elderly patients. This could lead to a risk of inefficacy. In particular, doses of ciprofloxacin appear to be too strongly reduced in patients with renal failure to ensure the effectiveness of treatment for infection with bacteria presenting an MIC .1 mg/L. However, as our model does not take into account the antibiotic toxicity, which has been reported as dose-dependent, 35 -37 toxic risk when using higher doses has not been studied. The simulations were undertaken assuming the choice of the most conservative drug regimen proposed either in EUCAST recommendations or in the French Summary of Product Characteristics for each evaluated drug. While more aggressive strategies could be used if necessary, these conservative schemes were selected for simulation because their use was considered very likely in the case of elderly patients for whom a greater risk of adverse effects is expected. 38 More favourable results would have been found with more aggressive regimens. Similarly, the choice of a target of at least 100 for fAUC/MIC could be discussed: regardless of the susceptibility of the bacteria causing the infection, a higher or lower target may be more appropriate depending on the location and severity of infection. 39 Finally, even if the criterion used (fAUC/MIC) is considered to be correlated with clinical response, a clinical study would be needed to validate this hypothesis and to suggest a strategy more suited to this population.
Conclusions
Fluoroquinolones are widely used in geriatric patients, but because of a renal-dominant elimination pathway, elderly patients have been shown to have changes in fluoroquinolone pharmacokinetic parameters, with a reduced rate of renal elimination. Therefore reduced dosage regimens are often used to account for the decline in renal elimination.
Using Monte Carlo simulations, our study showed that dosage reductions according to renal function are generally well adapted to geriatric patients when considering bacteria with low MICs, but with higher MICs, the proposed regimens for ciprofloxacin and ofloxacin could be inefficient for patients with moderate or severe renal impairment.
This suggests that the proposed dosage reduction does not allow the same exposure to be achieved in these patients as in patients without renal impairment. Whereas a clinical study is needed to validate this hypothesis, this relative under-exposure could be responsible for treatment failure or facilitate the development of resistant strains. When resistant organisms are found, tailored therapy should be considered.
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